GE Deals Biopharma Biz To Danaher For $21.4Bn; Planned Healthcare IPO Probably Won't Happen
Executive Summary
The proposed IPO for GE's healthcare business could be off the table, CEO Lawrence Culp said as GE announced plans to sell its biopharma business to Danaher for $21.4bn. The deal will provide the conglomerate with a much needed cash injection to handle its rising debts.
You may also be interested in...
Device/Diagnostics Quarterly Dealmaking Statistics, Q1 2019
Device financing totaled $1.6bn for the first quarter of 2019. Late-stage venture rounds were the most active category, led by Nuvaira's $79m Series E financing. Merger and acquisition activity reached $7.3bn; in the largest transaction of the quarter, Ethicon acquired Auris Health for up to $6bn. Diagnostics/research financing reached $1.7bn, and ten diagnostics/research tools companies were acquired, five of which together were valued at $22.6bn.
GE Healthcare Sets Out Its Software And AI Ambitions
GE Healthcare is using its artificial intelligence platform Edison to power a new generation of medical imaging apps and devices. At the annual European Congress of Radiology (ECR), In Vivo met with Mathias Goyen, GE Healthcare’s chief medical officer, Europe, to discuss the future of AI in radiology and how technology will transform practice.
GE Healthcare Sets Out Its Software And AI Ambitions At ECR 2019
GE Healthcare is using its artificial intelligence platform Edison to power a new generation of medical imaging apps and devices. At the annual European Congress of Radiology (ECR), Medtech Insight met with Mathias Goyen, GE Healthcare’s chief medical officer, Europe to discuss the future of AI in radiology and how technology will transform practice.